Inventiva presents its research on lanifibranor at the EASL Congress 2026

The biopharmaceutical company Inventiva, listed on Euronext Paris and NASDAQ, announced the presentation of two abstracts at the EASL Congress 2026 in Barcelona. This congress, organized by the European Association for the Study of the Liver, will take place from May 27 to 30. The abstracts focus on the development of therapies for metabolic steatohepatitis associated with steatohepatitis (MASH) using lanifibranor.

Studies evaluate the improvements induced by lanifibranor on histological and metabolic parameters, independent of weight changes. Furthermore, an ultrastructural assessment of hepatic endothelial cell capillarization highlights the potential of lanifibranor to modulate this condition. Inventiva is recognized for its expertise in oral therapies targeting PPAR receptors and has a promising portfolio with accelerated therapeutic status.